Declared Dividend • May 20
First half dividend of UK£0.13 announced Dividend of UK£0.13 is the same as last year. Ex-date: 28th May 2026 Payment date: 26th June 2026 Dividend yield will be 9.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (106% cash payout ratio). The dividend has increased by an average of 2.4% per year over the past 10 years. However, payments have been volatile during that time. Anuncio • May 20
Victrex plc Announces Stepping Down of David Thomas as Non-Executive Director, Effective May 18, 2026 Victrex PLC announces that David Thomas has informed the Board that he has stepped down as a Non-executive director of the Company with immediate effect on May 18, 2026, due to ill health. David Thomas was appointed as Non-executive director in 2018. Anuncio • May 12
Victrex plc Announces Interim Dividend for the Six Months Ended 31 March 2026, Payable on 26 June 2026 Victrex plc announced interim dividend for the six months ended 31 March 2026 of 13.42 pence per share will be paid on 26 June 2026 to shareholders on the register at the close of business on 29 May 2026. This dividend will be recognised in the period in which it is approved. Anuncio • Feb 11
Victrex plc Announces Changes to Its Board and Committee Spirax Group plc announced the appointment of Maria Antoniou, Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director of Victrex plc with effect from 1 September 2026. Victrex plc also announced the appointment of Peter Kiernan as non-executive director and David Thomas, non-executive director and Chair of the Audit Committee, will retire from the Board on 1 July 2026, and Peter will succeed David as Chair of the Audit Committee from that date. Peter Kiernan has significant experience in executive and non-executive roles. He had a 30 year career in investment banking with a focus on M&A and general corporate finance advice, including senior roles at S.G. Warburg/UBS, Goldman Sachs, Lazard and Hawkpoint Partners/Canaccord Genuity. He started his career at Peat, Marwick, Mitchell where he qualified as a Chartered Accountant. He holds an MA in Natural Sciences (Chemistry) from Cambridge University. Peter has held several advisory and non-executive positions. He currently holds senior advisory roles at Egon Zehnder and OMERS Private Equity (Europe). Prior non-executive roles include Tungsten Corporation, a public company where he was Audit Committee Chair and Senior Independent Director, Lifeways Group, a private equity owned business where he was Audit Committee Chair and Chair, and Business LDN where he was Chair of the Finance Committee. MariaAntoniou has extensive experience in both executive and non-executive roles within UK plc Boards. She is currently Chief Human Resources Officer at Morgan Advanced Materials plc and a non-executive director at FTSE 100 listed Spirax Group plc. Until last year she was a non-executive director of NATS (the National Air Traffic Service). Maria has a strong background in international industrial businesses, having worked in significant roles at Ford, Jaguar Land Rover and E.ON. Her experience spans across various sectors, including automotive, energy, and advanced materials, which gives her a comprehensive understanding of the challenges and opportunities within industries aligned to Victrex's end-markets. Anuncio • Feb 06
Jakob Sigurdsson Steps Down as an Executive Director of Victrex Plc, Effective from February 6, 2026 Coats Group PLC announces that it has been notified that Jakob Sigurdsson, a Non-Executive Director of the Company, has on February 6, 2026, stepped down as an Executive Director of Victrex plc. Anuncio • Oct 22
Victrex plc, Annual General Meeting, Feb 06, 2026 Victrex plc, Annual General Meeting, Feb 06, 2026. Anuncio • Dec 06
Victrex plc, Annual General Meeting, Feb 07, 2025 Victrex plc, Annual General Meeting, Feb 07, 2025. Anuncio • Dec 03
Victrex plc Proposes Final Dividend for the Fiscal Year 2025, Payable on 21 February 2025 Victrex plc at its AGM to be held on 7 February 2025, proposed final dividend at 46.14 pence per share (fiscal year 2024: 46.14 pence per share), with an Ex-dividend date: 23 January 2025, Record date: 24 January 2025 and Payment of final dividend: 21 February 2025. Anuncio • Sep 18
Victrex plc Announces in Partnership with Maxx Orthopedics Inc, FDA Grants IDE Approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component as Staged Study Victrex plc announced that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components. The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025. Anuncio • Sep 06
Victrex plc to Report Fiscal Year 2024 Results on Dec 03, 2024 Victrex plc announced that they will report fiscal year 2024 results on Dec 03, 2024 New Risk • May 16
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 44% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin). Declared Dividend • May 16
First half dividend of UK£0.13 announced Dividend of UK£0.13 is the same as last year. Ex-date: 30th May 2024 Payment date: 28th June 2024 Dividend yield will be 4.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (169% earnings payout ratio) nor is it covered by cash flows (411% cash payout ratio). The dividend has increased by an average of 4.4% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 87% to bring the payout ratio under control. EPS is expected to grow by 143% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Anuncio • May 15
Victrex plc Announces Interim Dividend , Payable on June 28, 2024 Victrex plc announced that an interim dividend of 13.42 pence per share (First half 2023: 13.42 pence) will be paid on 28 June 2024 to shareholders on the register at the close of business on 31 May 2024. This dividend will be recognised in the period in which it is approved. New Risk • May 13
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Dividend yield: 4.6% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 169% Cash payout ratio: 411% Minor Risk Profit margins are more than 30% lower than last year (11% net profit margin). Anuncio • Mar 15
Victrex plc Appoints Urmi Prasad Richardson as Non-Executive Director, Effective from May 1, 2024 Victrex plc announced that Urmi Prasad Richardson has been appointed as a non-executive director of the Board, effective from May 1, 2024. Urmi has a wealth of global experience in executive and non-executive roles over a 25 year period. She has a particular focus on science, medical and innovation based businesses. Urmi is currently President EMEA of Thermo Fisher Scientific, a world leader in serving science, with products which help accelerate life science research and improve patient health. Her executive career includes roles at The Linde Group, where she was Global Head of Healthcare, at Novartis and Foundation Medicine (a Roche company). She started her career with G.D. Searle (a Pfizer company) and has worked throughout Europe and the US. Urmi has extensive experience in strategy, business development and product commercialisation in Europe, Asia and North America. Urmi holds a number of advisory Board roles at unlisted organizations in the sectors of longevity, blockchain, and targeted therapy in oncology. Her previous non-executive roles include Linde Healthcare. Anuncio • Feb 27
Victrex plc to Report First Half, 2024 Results on May 13, 2024 Victrex plc announced that they will report first half, 2024 results on May 13, 2024 Anuncio • Feb 09
Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024 Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024. Upcoming Dividend • Jan 18
Upcoming dividend of UK£0.46 per share at 4.4% yield Eligible shareholders must have bought the stock before 25 January 2024. Payment date: 23 February 2024. Payout ratio is on the higher end at 84%, and the cash payout ratio is above 100%. Trailing yield: 4.4%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (3.2%). Reported Earnings • Jan 11
Full year 2023 earnings released: EPS: UK£0.71 (vs UK£0.88 in FY 2022) Full year 2023 results: EPS: UK£0.71 (down from UK£0.88 in FY 2022). Revenue: UK£307.0m (down 10.0% from FY 2022). Net income: UK£61.7m (down 19% from FY 2022). Profit margin: 20% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 4.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 07
Full year 2023 earnings released: EPS: UK£0.71 (vs UK£0.88 in FY 2022) Full year 2023 results: EPS: UK£0.71 (down from UK£0.88 in FY 2022). Revenue: UK£307.0m (down 10.0% from FY 2022). Net income: UK£61.7m (down 19% from FY 2022). Profit margin: 20% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 4.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Buying Opportunity • Oct 18
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be UK£17.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 3.3% per annum. Earnings is also forecast to grow by 9.8% per annum over the same time period. Anuncio • Oct 14
Victrex Announces New Product Grade Launch, Victrex Pharmaceutical Contact (PC)101 (VICTREX PC101), Developed Exclusively for the Drug Delivery Device Market Victrex plc have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications. This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products. VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago. PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing. Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond. Buying Opportunity • Sep 26
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be UK£17.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings is also forecast to grow by 10% per annum over the same time period. Anuncio • Jul 07
Victrex plc to Report Q4, 2023 Results on Dec 04, 2023 Victrex plc announced that they will report Q4, 2023 results on Dec 04, 2023 Buying Opportunity • Jun 19
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be UK£18.09, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 2.8%. For the next 3 years, revenue is forecast to grow by 4.2% per annum. Earnings is also forecast to grow by 11% per annum over the same time period. Upcoming Dividend • May 18
Upcoming dividend of UK£0.13 per share at 3.8% yield Eligible shareholders must have bought the stock before 25 May 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.4%). Reported Earnings • May 09
First half 2023 earnings released: EPS: UK£0.39 (vs UK£0.43 in 1H 2022) First half 2023 results: EPS: UK£0.39 (down from UK£0.43 in 1H 2022). Revenue: UK£162.2m (up 1.3% from 1H 2022). Net income: UK£33.7m (down 11% from 1H 2022). Profit margin: 21% (down from 24% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jan 13
Upcoming dividend of UK£0.46 per share Eligible shareholders must have bought the stock before 19 January 2023. Payment date: 17 February 2023. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (5.4%). Higher than average of industry peers (2.8%). Reported Earnings • Jan 09
Full year 2022 earnings released: EPS: UK£0.88 (vs UK£0.84 in FY 2021) Full year 2022 results: EPS: UK£0.88 (up from UK£0.84 in FY 2021). Revenue: UK£341.0m (up 11% from FY 2021). Net income: UK£76.2m (up 4.1% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 12% per year. Reported Earnings • Dec 07
Full year 2022 earnings released: EPS: UK£0.88 (vs UK£0.84 in FY 2021) Full year 2022 results: EPS: UK£0.88 (up from UK£0.84 in FY 2021). Revenue: UK£341.0m (up 11% from FY 2021). Net income: UK£76.2m (up 4.1% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 10% per year. Anuncio • Dec 06
Victrex plc, Annual General Meeting, Feb 10, 2023 Victrex plc, Annual General Meeting, Feb 10, 2023. Upcoming Dividend • May 19
Upcoming dividend of UK£0.13 per share Eligible shareholders must have bought the stock before 26 May 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 74% but the company is paying out more than the cash it is generating. Trailing yield: 3.5%. Lower than top quartile of British dividend payers (4.8%). Higher than average of industry peers (2.8%). Reported Earnings • May 10
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down UK£40.7m from profit in 1H 2021). Profit margin: (down from 27% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.4% compared to a 18% decline forecast for the industry in the United Kingdom. Recent Insider Transactions • Feb 23
CEO & Executive Director recently bought UK£53k worth of stock On the 21st of February, Jakob Sigurdsson bought around 3k shares on-market at roughly UK£18.93 per share. This was the largest purchase by an insider in the last 3 months. Jakob has been a buyer over the last 12 months, purchasing a net total of UK£117k worth in shares. Buying Opportunity • Jan 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 5.6%. The fair value is estimated to be UK£27.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 4.5% per annum over the last 3 years. Earnings per share has declined by 23% per annum over the last 3 years. Upcoming Dividend • Jan 20
Upcoming dividend of UK£0.96 per share Eligible shareholders must have bought the stock before 27 January 2022. Payment date: 18 February 2022. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (2.0%). Reported Earnings • Jan 14
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: UK£0.84 (up from UK£0.63 in FY 2020). Revenue: UK£306.3m (up 15% from FY 2020). Net income: UK£73.2m (up 35% from FY 2020). Profit margin: 24% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 3.7% compared to a 2.8% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Reported Earnings • Dec 08
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: UK£0.84 (up from UK£0.63 in FY 2020). Revenue: UK£306.3m (up 15% from FY 2020). Net income: UK£73.2m (up 35% from FY 2020). Profit margin: 24% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 3.0% compared to a 2.1% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Upcoming Dividend • May 27
Upcoming dividend of UK£0.13 per share Eligible shareholders must have bought the stock before 03 June 2021. Payment date: 30 June 2021. Trailing yield: 1.1%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (1.5%). Reported Earnings • May 12
First half 2021 earnings released: EPS UK£0.47 (vs UK£0.48 in 1H 2020) The company reported a soft first half result with weaker earnings, although revenues and profit margins were flat. First half 2021 results: Revenue: UK£150.9m (flat on 1H 2020). Net income: UK£40.7m (down 1.0% from 1H 2020). Profit margin: 27% (in line with 1H 2020). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Mar 02
CEO & Executive Director recently bought UK£64k worth of stock On the 1st of March, Jakob Sigurdsson bought around 3k shares on-market at roughly UK£21.41 per share. This was the largest purchase by an insider in the last 3 months. This was Jakob's only on-market trade for the last 12 months. Analyst Estimate Surprise Post Earnings • Jan 13
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.8% decline forecast for the Chemicals industry in the United Kingdom. Analyst Estimate Surprise Post Earnings • Jan 13
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.3% decline forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Jan 08
Full year 2020 earnings released: EPS UK£0.63 The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Jan 08
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3% compared to a 9.7% decline forecast for the Chemicals industry in the United Kingdom. Is New 90 Day High Low • Jan 07
New 90-day high: UK£24.48 The company is up 25% from its price of UK£19.63 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.25 per share. Is New 90 Day High Low • Dec 23
New 90-day high: UK£23.30 The company is up 28% from its price of UK£18.24 on 24 September 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.37 per share. Reported Earnings • Dec 11
Full year 2020 earnings released: EPS UK£0.63 The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Dec 11
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 3.4% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Is New 90 Day High Low • Dec 04
New 90-day high: UK£21.12 The company is up 9.0% from its price of UK£19.44 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£19.43 per share.